Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
May 2021
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical programBeovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus…
-
Media ReleaseNovartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalizationThe study plans to enroll 2100 patients, with 400…
-
Media ReleaseNovartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancerOverall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be…
-
Media ReleaseSandoz announces plans to further strengthen its antibiotics manufacturing setup in EuropeSandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens…
-
Media ReleaseNovartis reaches milestone delivery of 1 billion courses of antimalarial treatmentNovartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based…
-
Media ReleaseUS Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) caseDecision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by…
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicineSandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts…
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus afliberceptIn KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic…
April 2021
-
Key ReleaseNovartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with…
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experienceSMART study to extend data beyond patient population studied in clinical trials New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world…
-
Media ReleaseKesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMSKesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra…
Pagination
- ‹ Previous page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- …
- 88
- › Next page